Green Cross to conduct clinical trial of anti-anemic agent
Co-developed by Genexine, GC1113 is a recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion. The fusion prote...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
